Society Journal 1 Archives - Page 7 of 8 - PulmCCM

Society Journal 1 Articles

Apr 262011

Pulmonary hypertension is often “diagnosed” with a tricuspid regurgitant jet velocity > 2.5 m/s on echocardiogram. Bossone et al found that 76 of 615 (12%) trained athletes (strength or endurance) exceeded this number, and suggest the upper limit of normal should be 40 mm Hg in endurance athletes. CHEST 2011;139:788-794.

Apr 222011

Interviewing 100 patients or their surrogates in the ICU, 85% of whom were “full code,” Gehlbach et al found 16% of patients’ code status in the chart did not correlate with their expressed preferences during the interview (10 wanted less care, 6 wanted more). Respondents’ average prediction for their survival should they have a cardiac [... read more]

Apr 062011

Fang et al prospectively observed 126 patients undergoing lung transplant at 9 U.S. centers. PA pressure was obtained invasively in the OR just after transplant. Those who developed grade 3 primary graft dysfunction at 72 hours (1′ endpoint) had mPAP of 38.5 mm Hg, compared to 29.6 for those who did not; the relationship persisted [... read more]

Mar 192011

THIS STUDY HAS BEEN RETRACTED. Kupfer et al looked retrospectively at 168 vented patients with transudative pleural effusions at Maimonides in Brooklyn. The half that got chest tubes (with an average of 1,200 mL drained) spent 3.8 days on the vent, vs 6.5 days for the group that got only thoracentesis, with no complications reported. [... read more]

Mar 012011

Tashkin et al randomized 504 patients at 27 centers with COPD and FEV1 > 49% to varenicline or placebo for 12 weeks, with 52 weeks follow up. Smoking cessation / abstinence rate (carbon monoxide-confirmed) was 42% vs 9% in weeks 9 – 12 (1′ endpoint), and 19% vs. 6% in weeks 9 – 52 (p<0.0001). [... read more]

Feb 162011

Ciclesonide, a new inhaled corticosteroid that seems to cause thrush less often than others, reached for equivalency with salmeterol/fluticasone in mild persistent asthma. Ciclesonide was better than placebo in controlling asthma but Advair users had a longer time to first asthma exacerbation. CHEST 2011;139: online supplement. A Cochrane review on ciclesonide could not establish its [... read more]

Jul 032010

Priou et al followed 130 patients with OHS after initiation with noninvasive positive pressure ventilation. Mean follow up was 4 years. Most (96) were started on NPPV in the stable state; 38 had had an acute hypercapneic exacerbation. Survival at 1 year was 97.5%; 2 years (93%); 3 years (88%); 5 years (77%). The large [... read more]